Protocol Ledger

NCT07554495 · Phase III · RECRUITING

Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents

Interventional Phase III clinical trial protocol NCT07554495 sponsored by Alfasigma S.p.A in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-05-21 Enrollment: 65 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07554495
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)65 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07554495
Protocol FieldVerified Registry Value
NCT IdentifierNCT07554495
Consolidated Lead SponsorAlfasigma S.p.A
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment65 participants (ESTIMATED)
Registered Start Date2026-05-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07554495
Hospital Research SiteLocationSite Profile
UZ LeuvenLeuven, BelgiumOpen Hospital Dossier ->
Vseobecna fakultni nemocnice v PrazePrague, CzechiaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI